GLP-1 drugs are praised as obesity breakthroughs but criticized over cost, shortages, long-term safety, stigma and unequal access.
A new class of anti-obesity medicines, led by GLP-1 receptor agonists such as semaglutide and dual GIP/GLP-1 drugs such as tirzepatide, has moved weight loss from the margins of lifestyle coaching and bariatric surgery into mainstream chronic-disease medicine. Originally developed for type 2 diabetes, these drugs mimic gut hormones that regulate appetite, satiety, glucose metabolism, and possibly inflammation. Large trials showing average weight loss of roughly 15% with semaglutide and more than 20% with tirzepatide triggered rapid public demand, employer and insurer debates, supply shortages, and a surge of telehealth prescribing.
The loudest debate often frames the issue as either miracle cure or dangerous vanity drug, but the more accurate picture is that these medicines are powerful chronic-disease tools with uneven benefits, incomplete long-term evidence, and major distribution problems. They are not simply appetite suppressants, and they are not a substitute for nutrition, exercise, sleep, mental-health support, or public-health policy. They may reshape cardiology, endocrinology, hepatology, orthopedics, fertility care, and even addiction research, but their impact depends on who can get them, who stays on them, and whether health systems can manage monitoring at scale.
Ozempic-style drugs are hailed as obesity breakthroughs but criticized over cost, shortages, side effects, beauty culture and who gets access.
Ozempic-style drugs are hailed as a breakthrough for obesity while critics warn about cost, shortages, side effects and lifelong dependency.
Ozempic-style drugs are praised as obesity breakthroughs while critics warn about cost, shortages, side effects, long-term use and beauty-culture pressure.
Ozempic-style drugs are hailed as obesity breakthroughs but criticized over cost, access, long-term safety and pressure to medicalize body weight.